While reporting financial results for the fourth quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) initiated its adjusted earnings and sales growth guidance for the first quarter, and for the full-year 2026.
For the first quarter, the company estimates adjusted earnings in a range of $0.78 to $0.80 per share on net sales growth of about 10.5 to 12.0 percent, with organic net sales growth of 8.5 to 10.0 percent.
On average, analysts polled expect earnings of $0.80 per share on revenue growth of 11.57 percent to $5.20 billion for the quarter. Analysts' estimates typically exclude special items.
Looking ahead to fiscal 2026, the company now projects adjusted earnings in a range of $3.43 to $3.49 per share on net sales growth of about 10.5 to 11.5 percent, with organic net sales growth of 10 to 11 percent.
The Street is looking for earnings of $3.47 per share on revenue growth of 11.55 percent to $22.39 billion for the quarter.
In Wednesday's pre-market trading, BSX is trading on the NYSE at $90.00, down $1.59 or 1.74 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
January 30, 2026 15:51 ET The Federal Reserve policy decision was the main event in the final week of January, which saw a heavy flow of economics news. Several data reflecting the trends in the U.S. economy were also released during the week. The interest rate decision from Canada also was in focus. In Europe, economic sentiment data gained attention. The policy decision from Singapore was the highlight in Asia.